FOLH1 and metastatic prostate carcinoma: [225Ac]Ac-PSMA-617 and [177Lu]Lu-PSMA-617 were compared alone or combined (i.e. tandem α- and β-particle therapy) for treating metastatic prostate cancer tumours in NSG mice (Meyer et al. 2023).